Show simple item record

dc.contributor.authorPopat, R.
dc.contributor.authorWilson, W.
dc.contributor.authorCamilleri, M.
dc.contributor.authorDe Tute, R.
dc.contributor.authorPang, G.
dc.contributor.authorJenner, R.
dc.contributor.authorDadaga, T.
dc.contributor.authorKamora, S.
dc.contributor.authorStreetly, M.
dc.contributor.authorRamasamy, K.
dc.contributor.authorPhillips, Elizabeth H
dc.contributor.authorChapman, M.
dc.contributor.authorBygrave, C.
dc.contributor.authorCavenagh, J.
dc.contributor.authorSive, J.
dc.contributor.authorBenjamin, R.
dc.contributor.authorEccersley, L.
dc.contributor.authorHassan, S.
dc.contributor.authorWillis, F.
dc.contributor.authorClifton-Hadley, L.
dc.contributor.authorOwen, R.
dc.contributor.authorYong, K.
dc.date.accessioned2022-01-11T11:59:41Z
dc.date.available2022-01-11T11:59:41Z
dc.date.issued2021en
dc.identifier.citationPopat R, Wilson W, Camilleri M, Tute RD, Pang G, Jenner R, et al. OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM) Vol. 21, Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2021. p. S2–3.en
dc.identifier.doi10.1016/S2152-2650(21)02077-2en
dc.identifier.urihttp://hdl.handle.net/10541/624848
dc.description.abstractBackground The role of upfront ASCT for NDTE MM remains under evaluation with high MRD rates following novel induction and consolidation (cons) strategies. K maintenance represents an alternative strategy to lenalidomide maintenance. The CARDAMON trial investigated K maintenance following KCd induction plus either ASCT or KCd cons. Methods NDTE pts received 4 x KCd induction (K 20/56 mg/m2 biweekly, C 500 mg D 1,8,15, d 40mg weekly) before 1:1 randomisation to ASCT or 4 x KCd cons followed by 18 cycles K maintenance (56mg/m2 D1,8,15). Flow cytometric MRD (10-5) was assessed post induction, pre-maintenance and at 6 months maintenance. Primary endpoints were ≥VGPR post induction and 2-year PFS from randomisation. Secondary endpoints included improvements in disease response and MRD conversion following ASCT/ cons and maintenance. Results 281 patients were registered, with 218 randomised to either ASCT or cons. The median PFS for ASCT was not yet reached vs 3.4 years for cons, with cons failing to show non-inferiority (difference in 2-year PFS 6.5%, 70% CI 1.0% to 11.1%). 196 patients received K maintenance (99 ASCT, 97 cons), 17 remain on treatment. A median of 16 cycles (1-18) were given over a median of 15.9 months (0-21.5). COVID-19 led to maintenance treatment interruptions in 41 (8 ASCT, 6 Cons) and treatment discontinuation in 15 (9 ASCT, 6 Cons). The median K dose given was 50.6mg/m2 and was similar across both arms (51.2 vs 49.4mg/m2, p=0.03). K maintenance was discontinued for PD in 14.1% (ASCT) vs 22.7% (cons), and for adverse events (AEs) in 7.1% (ASCT) vs 4.1% (cons). Most common AEs were hypertension and infections and more ≥G3 AEs were noted in ASCT vs cons (p=0.01). Patient/ clinician withdrawals from maintenance were low but occurred more in the ASCT arm (9.1% vs 1%). MRD neg patients post ASCT/ Cons had a longer PFS than MRD pos (p=0.002); with a higher MRD neg rate in the ASCT arm (53.6% vs 35.1% in Cons, p=0.01). MRD neg patients at 6 months post maintenance also had longer PFS (p=0.004 cf MRD pos patients); again with higher MRD neg rates in the ASCT arm (58.1% ASCT vs 40.5% Cons, p=0.02). There was no difference in PFS for MRD neg patients according to treatment arm from PBSCH, post-ASCT/ Cons or 6 months maintenance timepoints. Overall, 27.8% of MRD pos patients converted to MRD neg post ASCT/ Cons with more converting with ASCT (39.1% ASCT vs 16.1%, p=0.004). 23.5% of MRD pos patients converted to neg during maintenance (30.6% ASCT, 17.8%: p=0.2). Maintenance of MRD negativity over the first 6 months was similar between ASCT and Cons arms (p=0.3). There was no evidence that the timing of achievement of MRD negativity impacted PFS. Conclusions K maintenance at 56mg/m2 weekly was deliverable and tolerable, with continued higher MRD neg rates at 6 months post-ASCT compared to post-Cons. However more ≥G3 AEs and discontinuations for AEs/ patient choice were noted for K maintenance after ASCT.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/S2152-2650(21)02077-2en
dc.titleCARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniversity College London Hospitals NHS Foundation Trust, UKen
dc.identifier.journalClinical Lymphoma Myeloma & Leukemiaen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record